A Phase I/IIa, Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Moderate Alzheimer's Disease
NKGen Biotech, Inc.
Summary
The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are: 1. Is SNK01 safe and tolerable when administered every 3 weeks for up to 1 year as an intravenous infusion 2. Can SNK01 administration improve cognitive assessment scores and biomarkers
Eligibility
- Age range
- 40–85 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. The participant or their legally authorized representative must be willing and able to give their informed consent in writing and comply with the requirements of this study protocol. Informed consent for participants or their legally authorized representative and caregivers will be obtained before any trial-related activity. (Trial-related activities are any procedure that would not be performed during normal treatment of the participant). 2. Participants must have a reliable study partner/caregiver (per investigator judgement for instance a family member, partner etc.,…
Interventions
- BiologicalSNK01
SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug
- OtherPlacebo
Sodium Lactate Hartmann's Solution
Locations (5)
- Behavioral Research Specialists, LLCGlendale, California
- Syrentis Clinical ResearchSanta Ana, California
- Valiance Clinical ResearchTarzana, California
- AdventHealth Research InstituteOrlando, Florida
- Ottawa Memory ClinicOttawa, Ontario